Skip to main content
Erschienen in: Heart Failure Reviews 1/2015

01.01.2015

Amino acids and derivatives, a new treatment of chronic heart failure?

verfasst von: Valentina Carubelli, Anna Isotta Castrini, Valentina Lazzarini, Mihai Gheorghiade, Marco Metra, Carlo Lombardi

Erschienen in: Heart Failure Reviews | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Amino acids play a key role in multiple cellular processes. Amino acids availability is reduced in patients with heart failure (HF) with deleterious consequences on cardiac and whole-body metabolism. Several metabolic abnormalities have been identified in the failing heart, and many of them lead to an increased need of amino acids. Recently, several clinical trials have been conducted to demonstrate the benefits of amino acids supplementation in patients with HF. Although they have shown an improvement of exercise tolerance and, in some cases, of left ventricular function, they have many limitations, namely small sample size, differences in patients’ characteristics and nutritional supplementations, and lack of data regarding outcomes. Moreover recent data suggest that a multi-nutritional approach, including also antioxidants, vitamins, and metals, may be more effective. Larger trials are needed to ascertain safety, efficacy, and impact on prognosis of such an approach in HF.
Literatur
1.
Zurück zum Zitat Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146PubMedCrossRef Rosamond W, Flegal K, Furie K et al (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146PubMedCrossRef
2.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847PubMedCrossRef
3.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B et al (2013) ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852PubMedCrossRef Yancy CW, Jessup M, Bozkurt B et al (2013) ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852PubMedCrossRef
4.
5.
Zurück zum Zitat Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52:428–434PubMedCrossRef Fang J, Mensah GA, Croft JB, Keenan NL (2008) Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52:428–434PubMedCrossRef
6.
Zurück zum Zitat Heidenreich PA, Albert NM, Allen LA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6:606–619PubMedCentralPubMedCrossRef Heidenreich PA, Albert NM, Allen LA et al (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6:606–619PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Jhund PS, Macintyre K, Simpson CR et al (2009) Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 119:515–523PubMedCrossRef Jhund PS, Macintyre K, Simpson CR et al (2009) Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 119:515–523PubMedCrossRef
8.
Zurück zum Zitat Ahmed A, Allman RM, Fonarow GC et al (2008) Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 14:211–218PubMedCentralPubMedCrossRef Ahmed A, Allman RM, Fonarow GC et al (2008) Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 14:211–218PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Soukoulis V, Dihu JB, Sole M et al (2009) Micronutrient deficiencies: an unmet need in heart failure. J Am Coll Cardiol 54:1660–1673PubMedCrossRef Soukoulis V, Dihu JB, Sole M et al (2009) Micronutrient deficiencies: an unmet need in heart failure. J Am Coll Cardiol 54:1660–1673PubMedCrossRef
11.
Zurück zum Zitat Taegtmeyer H, Harinstein ME, Gheorghiade M (2008) More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 101:3E–7EPubMedCrossRef Taegtmeyer H, Harinstein ME, Gheorghiade M (2008) More than bricks and mortar: comments on protein and amino acid metabolism in the heart. Am J Cardiol 101:3E–7EPubMedCrossRef
12.
Zurück zum Zitat Anker SD, Volterrani M, Pflaum CD et al (2001) Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. JACC 38(2):443–452PubMedCrossRef Anker SD, Volterrani M, Pflaum CD et al (2001) Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. JACC 38(2):443–452PubMedCrossRef
13.
Zurück zum Zitat Pasini E, Aquilani R, Dioguardi FS (2004) Amino acids: chemistry and metabolism in normal and hypercatabolic states. Am J Cardiol 93(suppl):3A–5APubMedCrossRef Pasini E, Aquilani R, Dioguardi FS (2004) Amino acids: chemistry and metabolism in normal and hypercatabolic states. Am J Cardiol 93(suppl):3A–5APubMedCrossRef
14.
Zurück zum Zitat Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS (2003) Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J 4:232–235PubMed Pasini E, Aquilani R, Gheorghiade M, Dioguardi FS (2003) Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. Ital Heart J 4:232–235PubMed
15.
Zurück zum Zitat Ingwall JS, Shen W (2010) On energy circuits in the failing myocardium. Eur J Heart Fail 12(12):1268–1270PubMedCrossRef Ingwall JS, Shen W (2010) On energy circuits in the failing myocardium. Eur J Heart Fail 12(12):1268–1270PubMedCrossRef
16.
Zurück zum Zitat Razeghi P, Sharma S, Ying J et al (2003) Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108:2536–2541PubMedCrossRef Razeghi P, Sharma S, Ying J et al (2003) Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108:2536–2541PubMedCrossRef
17.
Zurück zum Zitat Herrero P, Dence CS, Coggan AR et al (2007) L-3-11C-lactate as a PET tracer of myocardial metabolism: a feasibility study. J Nucl Med 48(12):2046–2055PubMedCrossRef Herrero P, Dence CS, Coggan AR et al (2007) L-3-11C-lactate as a PET tracer of myocardial metabolism: a feasibility study. J Nucl Med 48(12):2046–2055PubMedCrossRef
18.
Zurück zum Zitat Kalantar-Zadeh K, Anker SD, Horwich TB et al (2008) Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 101:89E–103EPubMedCrossRef Kalantar-Zadeh K, Anker SD, Horwich TB et al (2008) Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol 101:89E–103EPubMedCrossRef
19.
Zurück zum Zitat Hara K, Yonezawa K, Weng QP et al (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism [published correction appears in J Biol Chem 1998;273:22160]. J Biol Chem 273:14484–14494PubMedCrossRef Hara K, Yonezawa K, Weng QP et al (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism [published correction appears in J Biol Chem 1998;273:22160]. J Biol Chem 273:14484–14494PubMedCrossRef
20.
Zurück zum Zitat Flati V, Pasini E, D’Antona G et al (2008) Intracellular Mechanisms of Metabolism Regulation: the Role of Signaling via the Mammalian Target of Rapamycin Pathway and Other Routes. Am J Cardiol 101(suppl):16E–21EPubMedCrossRef Flati V, Pasini E, D’Antona G et al (2008) Intracellular Mechanisms of Metabolism Regulation: the Role of Signaling via the Mammalian Target of Rapamycin Pathway and Other Routes. Am J Cardiol 101(suppl):16E–21EPubMedCrossRef
21.
Zurück zum Zitat Harper AE, Miller RH, Block KP (1984) Branched-chain amino acid metabolism. Annu Rev Nutr 4:409–454PubMedCrossRef Harper AE, Miller RH, Block KP (1984) Branched-chain amino acid metabolism. Annu Rev Nutr 4:409–454PubMedCrossRef
22.
Zurück zum Zitat Baquet A, Lavoinne A, Hue L (1991) Comparison of the effects of various amino acids on glycogen synthesis, lipogenesis and ketogenesis in isolated rat hepatocytes. Biochem J 273(Pt 1):57–62PubMedCentralPubMed Baquet A, Lavoinne A, Hue L (1991) Comparison of the effects of various amino acids on glycogen synthesis, lipogenesis and ketogenesis in isolated rat hepatocytes. Biochem J 273(Pt 1):57–62PubMedCentralPubMed
23.
Zurück zum Zitat Huang Y, Zhou M, Sun H et al (2011) Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res 90(2):220–223PubMedCentralPubMedCrossRef Huang Y, Zhou M, Sun H et al (2011) Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? Cardiovasc Res 90(2):220–223PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Lu G, Ren S, Korge P et al (2007) A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev 21(7):784–796PubMedCentralPubMedCrossRef Lu G, Ren S, Korge P et al (2007) A novel mitochondrial matrix serine/threonine protein phosphatase regulates the mitochondria permeability transition pore and is essential for cellular survival and development. Genes Dev 21(7):784–796PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Sharma S, Guthrie PH, Chan SS et al (2007) Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 76:71–80PubMedCentralPubMedCrossRef Sharma S, Guthrie PH, Chan SS et al (2007) Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 76:71–80PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat She P, Reid TM, Bronson SK et al (2007) Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 6:181–194PubMedCentralPubMedCrossRef She P, Reid TM, Bronson SK et al (2007) Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 6:181–194PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Scholte HR, Rodrigues Pereira R, de Jonge PC et al (1990) Primary carnitine deficiency. J Clin Chem Clin Biochem 28:351–357PubMed Scholte HR, Rodrigues Pereira R, de Jonge PC et al (1990) Primary carnitine deficiency. J Clin Chem Clin Biochem 28:351–357PubMed
28.
Zurück zum Zitat Pion PD, Kittleson MD, Rogers QR, Morris JG (1987) Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 237:764–768PubMedCrossRef Pion PD, Kittleson MD, Rogers QR, Morris JG (1987) Myocardial failure in cats associated with low plasma taurine: a reversible cardiomyopathy. Science 237:764–768PubMedCrossRef
29.
Zurück zum Zitat Fascetti AL, Reed JR, Rogers QR et al (2003) Taurine deficiency in dogs with dilated cardiomyopathy: 12 cases. J Am Vet Med Assoc 223:1137–1141PubMedCrossRef Fascetti AL, Reed JR, Rogers QR et al (2003) Taurine deficiency in dogs with dilated cardiomyopathy: 12 cases. J Am Vet Med Assoc 223:1137–1141PubMedCrossRef
30.
Zurück zum Zitat Wyss M, Walliman T (1994) Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 133(134):51–56PubMedCrossRef Wyss M, Walliman T (1994) Creatine metabolism and the consequences of creatine depletion in muscle. Mol Cell Biochem 133(134):51–56PubMedCrossRef
31.
Zurück zum Zitat Arsenian MA (1997) Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40:265–286PubMedCrossRef Arsenian MA (1997) Carnitine and its derivatives in cardiovascular disease. Prog Cardiovasc Dis 40:265–286PubMedCrossRef
32.
Zurück zum Zitat Schonekess BO, Allard MF, Lopaschuk GD (1995) Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77:726–734PubMedCrossRef Schonekess BO, Allard MF, Lopaschuk GD (1995) Propionyl L-carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circ Res 77:726–734PubMedCrossRef
33.
Zurück zum Zitat Pepine CJ (1991) The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 13:2–18PubMed Pepine CJ (1991) The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 13:2–18PubMed
34.
Zurück zum Zitat Siliprandi N, Di Lisa F, Menabo R (1991) Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5(Suppl 1):11–15PubMedCrossRef Siliprandi N, Di Lisa F, Menabo R (1991) Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 5(Suppl 1):11–15PubMedCrossRef
35.
Zurück zum Zitat Allard ML, Jeejeebhoy NK, Sole MJ (2006) The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 11:75–82PubMedCrossRef Allard ML, Jeejeebhoy NK, Sole MJ (2006) The management of conditioned nutritional requirements in heart failure. Heart Fail Rev 11:75–82PubMedCrossRef
36.
Zurück zum Zitat Nascimben L, Ingwall JS, Pauletto P et al (1996) Creatine kinase system in failing and nonfailing human myocardium. Circulation 94:1894–1901PubMedCrossRef Nascimben L, Ingwall JS, Pauletto P et al (1996) Creatine kinase system in failing and nonfailing human myocardium. Circulation 94:1894–1901PubMedCrossRef
37.
Zurück zum Zitat Azuma J, Sawamura A, Awata N (1992) Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ 56:95–99CrossRef Azuma J, Sawamura A, Awata N (1992) Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ 56:95–99CrossRef
38.
Zurück zum Zitat Grimble RF, Jackson AA, Persaud C et al (1992) Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet. J Nutr 122:2066–2073PubMed Grimble RF, Jackson AA, Persaud C et al (1992) Cysteine and glycine supplementation modulate the metabolic response to tumor necrosis factor alpha in rats fed a low protein diet. J Nutr 122:2066–2073PubMed
39.
Zurück zum Zitat Visser M, Paulus WJ, Vermeulen MAR et al (2010) The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 12:1274–1281PubMedCrossRef Visser M, Paulus WJ, Vermeulen MAR et al (2010) The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 12:1274–1281PubMedCrossRef
40.
Zurück zum Zitat Johnson P, Fedyna JS, Schindzielorz A et al (1982) Regulation of muscle phosphorylase activity by carnosine and anserine. Biochem Biophys Res Commun 109:769–775PubMedCrossRef Johnson P, Fedyna JS, Schindzielorz A et al (1982) Regulation of muscle phosphorylase activity by carnosine and anserine. Biochem Biophys Res Commun 109:769–775PubMedCrossRef
41.
Zurück zum Zitat Stuenenburg HJ, Kunze K (1999) Concentration of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles. Arch Gerontol Geriatr 29:107–113CrossRef Stuenenburg HJ, Kunze K (1999) Concentration of free carnosine (a putative membrane-protective antioxidant) in human muscle biopsies and rat muscles. Arch Gerontol Geriatr 29:107–113CrossRef
42.
Zurück zum Zitat McFarland GA, Holliday R (1994) Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res 212:167–175PubMedCrossRef McFarland GA, Holliday R (1994) Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res 212:167–175PubMedCrossRef
43.
Zurück zum Zitat McFarland GA, Holliday R (1999) Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol 34:35–45PubMedCrossRef McFarland GA, Holliday R (1999) Further evidence for the rejuvenating effects of the dipeptide L-carnosine on cultured human diploid fibroblasts. Exp Gerontol 34:35–45PubMedCrossRef
44.
Zurück zum Zitat Quinn PR, Boldyrev AA, Formazuyk VE (1992) Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med 13:379–444PubMedCrossRef Quinn PR, Boldyrev AA, Formazuyk VE (1992) Carnosine: its properties, functions and potential therapeutic applications. Mol Aspects Med 13:379–444PubMedCrossRef
45.
Zurück zum Zitat Hipkiss AR, Brownson C (2000) A possible new role for the anti-ageing peptide carnosine. Cell Mol Life Sci 57:747–753PubMedCrossRef Hipkiss AR, Brownson C (2000) A possible new role for the anti-ageing peptide carnosine. Cell Mol Life Sci 57:747–753PubMedCrossRef
46.
Zurück zum Zitat Ziêba R, Wagrowska-Danilewicz M (2003) Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. Pol J Pharmacol 55:1079–1087PubMed Ziêba R, Wagrowska-Danilewicz M (2003) Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. Pol J Pharmacol 55:1079–1087PubMed
47.
Zurück zum Zitat Muller M, Bottcher OS, Weselmann S, Boker K, Schwarze M, Von zur Muhlen A, Manns MP (1999) Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 69:1194–1201PubMed Muller M, Bottcher OS, Weselmann S, Boker K, Schwarze M, Von zur Muhlen A, Manns MP (1999) Hypermetabolism in clinically stable patients with liver cirrhosis. Am J Clin Nutr 69:1194–1201PubMed
48.
Zurück zum Zitat Moulias R, Meaume S, Raynaud-Simon A (1999) Sarcopenia, hypermetabolism and aging. Z Gerontol Geriatr 6:425–432CrossRef Moulias R, Meaume S, Raynaud-Simon A (1999) Sarcopenia, hypermetabolism and aging. Z Gerontol Geriatr 6:425–432CrossRef
49.
Zurück zum Zitat Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534PubMedCrossRef Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534PubMedCrossRef
50.
Zurück zum Zitat Von Haehling S, Doehner W, Anker S (2007) Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73:298–309CrossRef Von Haehling S, Doehner W, Anker S (2007) Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res 73:298–309CrossRef
51.
Zurück zum Zitat Cicoira M, Kalra PR, Anker SD (2003) Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 9:219–226PubMedCrossRef Cicoira M, Kalra PR, Anker SD (2003) Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail 9:219–226PubMedCrossRef
52.
Zurück zum Zitat Isgaard J, Bergh CH, Caidahl K et al (1998) A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 19:1704–1711PubMedCrossRef Isgaard J, Bergh CH, Caidahl K et al (1998) A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 19:1704–1711PubMedCrossRef
53.
Zurück zum Zitat Osterziel KJ, Strohm O, Schuler J et al (1998) Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351:1233–1237PubMedCrossRef Osterziel KJ, Strohm O, Schuler J et al (1998) Randomised, double blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351:1233–1237PubMedCrossRef
54.
Zurück zum Zitat Frustaci A, Gentiloni N, Russo MA (1996) Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 335:672–673PubMedCrossRef Frustaci A, Gentiloni N, Russo MA (1996) Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 335:672–673PubMedCrossRef
55.
Zurück zum Zitat Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD et al (2003) Hormonal profile in patients with congestive heart failure. Int J Cardiol 87:179–183PubMedCrossRef Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD et al (2003) Hormonal profile in patients with congestive heart failure. Int J Cardiol 87:179–183PubMedCrossRef
56.
Zurück zum Zitat Malkin CJ, Pugh PJ, West JN et al (2003) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64CrossRef Malkin CJ, Pugh PJ, West JN et al (2003) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64CrossRef
57.
Zurück zum Zitat Caminiti G, Volterrani M, Iellamo F et al (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. J Am Coll Cardiol 54:919–927PubMedCrossRef Caminiti G, Volterrani M, Iellamo F et al (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. J Am Coll Cardiol 54:919–927PubMedCrossRef
58.
Zurück zum Zitat Doehner W, Rauchhaus M, Ponikowski P et al (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46:1019–1026PubMedCrossRef Doehner W, Rauchhaus M, Ponikowski P et al (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46:1019–1026PubMedCrossRef
59.
Zurück zum Zitat Swan JW, Anker SD, Walton C et al (1997) Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30:527–532PubMedCrossRef Swan JW, Anker SD, Walton C et al (1997) Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30:527–532PubMedCrossRef
60.
Zurück zum Zitat Mamas A, Deaton C, Rutter MK et al (2010) Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Cardiac Fail 16:761–768CrossRef Mamas A, Deaton C, Rutter MK et al (2010) Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated? J Cardiac Fail 16:761–768CrossRef
61.
Zurück zum Zitat Leyva F, Anker SD, Egerer K et al (1998) Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 19:1547–1551PubMedCrossRef Leyva F, Anker SD, Egerer K et al (1998) Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 19:1547–1551PubMedCrossRef
62.
Zurück zum Zitat Frankel DS, Vasan RS, D’Agostino RB et al (2009) Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 53:754–762PubMedCentralPubMedCrossRef Frankel DS, Vasan RS, D’Agostino RB et al (2009) Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 53:754–762PubMedCentralPubMedCrossRef
63.
Zurück zum Zitat Nagaya N, Uematsu M, Kojima M et al (2001) Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104:2034–2038PubMedCrossRef Nagaya N, Uematsu M, Kojima M et al (2001) Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 104:2034–2038PubMedCrossRef
64.
Zurück zum Zitat Vary TC, O’Neill P, Cooney RN, Maish G, Shumate M (1999) Chronic infusion of interleukin 1 induces hyperlactatemia and altered regulation of lactate metabolism in skeletal muscle. JPEN 23:213–217CrossRef Vary TC, O’Neill P, Cooney RN, Maish G, Shumate M (1999) Chronic infusion of interleukin 1 induces hyperlactatemia and altered regulation of lactate metabolism in skeletal muscle. JPEN 23:213–217CrossRef
65.
Zurück zum Zitat Stanley WC, Lopaschuk GD, McCormack JG (1997) Regulation of energy substrates metabolism in the diabetic heart. Cardiovasc Res 34:25–33PubMedCrossRef Stanley WC, Lopaschuk GD, McCormack JG (1997) Regulation of energy substrates metabolism in the diabetic heart. Cardiovasc Res 34:25–33PubMedCrossRef
66.
Zurück zum Zitat Aquilani R, Opasich C, Gualco A (2008) Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail 10:1127–1135PubMedCrossRef Aquilani R, Opasich C, Gualco A (2008) Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail 10:1127–1135PubMedCrossRef
67.
Zurück zum Zitat Opasich C, Aquilani R, Dossena M et al (1996) Biochemical analysis of muscle biopsy in overnight fasting patients with severe chronic heart failure. Eur Heart J 17:1686–1693PubMedCrossRef Opasich C, Aquilani R, Dossena M et al (1996) Biochemical analysis of muscle biopsy in overnight fasting patients with severe chronic heart failure. Eur Heart J 17:1686–1693PubMedCrossRef
68.
Zurück zum Zitat Aquilani R, Viglio S, Iadarola P et al (2008) Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 101(Suppl):104E–110EPubMedCrossRef Aquilani R, Viglio S, Iadarola P et al (2008) Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 101(Suppl):104E–110EPubMedCrossRef
69.
Zurück zum Zitat Orozco-Gutiérrez JJ, Castillo-Martínez L, Orea-Tejeda A et al (2010) Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J. 17(6):612–618PubMed Orozco-Gutiérrez JJ, Castillo-Martínez L, Orea-Tejeda A et al (2010) Effect of L-arginine or L-citrulline oral supplementation on blood pressure and right ventricular function in heart failure patients with preserved ejection fraction. Cardiol J. 17(6):612–618PubMed
71.
Zurück zum Zitat Harinstein ME, Berliner JI, Shah SJ et al (2008) Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observation in 11 patients. Am J Ther 15:206–213PubMedCrossRef Harinstein ME, Berliner JI, Shah SJ et al (2008) Normalization of ejection fraction and resolution of symptoms in chronic severe heart failure is possible with modern medical therapy: clinical observation in 11 patients. Am J Ther 15:206–213PubMedCrossRef
72.
Zurück zum Zitat Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139:S120–S123PubMedCrossRef Rizos I (2000) Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 139:S120–S123PubMedCrossRef
73.
Zurück zum Zitat Jeejeebhoy F, Keith M, Freeman M et al (2002) Nutrition supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 143:1092–1100PubMedCrossRef Jeejeebhoy F, Keith M, Freeman M et al (2002) Nutrition supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J 143:1092–1100PubMedCrossRef
74.
Zurück zum Zitat Witte KK, Nikitin NP, Parker AC et al (2005) The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26:2238–2244PubMedCrossRef Witte KK, Nikitin NP, Parker AC et al (2005) The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 26:2238–2244PubMedCrossRef
75.
Zurück zum Zitat Sukkar SG, Gallo F, Borrini C et al (2012) Effects of a new mixture of essential amino acids (Aminotrofic(®)) in malnourished haemodialysis patients. Med J Nutr Metab 5(3):259–266CrossRef Sukkar SG, Gallo F, Borrini C et al (2012) Effects of a new mixture of essential amino acids (Aminotrofic(®)) in malnourished haemodialysis patients. Med J Nutr Metab 5(3):259–266CrossRef
76.
Zurück zum Zitat Hiroshige K, Sonta T, Suda T et al (2001) Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 16(9):1856–1862PubMedCrossRef Hiroshige K, Sonta T, Suda T et al (2001) Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 16(9):1856–1862PubMedCrossRef
77.
Zurück zum Zitat Leenders M, van Loon LJ (2011) Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev 69(11):675–689PubMedCrossRef Leenders M, van Loon LJ (2011) Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev 69(11):675–689PubMedCrossRef
78.
Zurück zum Zitat Macotela Y, Emanuelli B, Bång AM et al (2011) Dietary leucine–an environmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One 6(6):e21187PubMedCentralPubMedCrossRef Macotela Y, Emanuelli B, Bång AM et al (2011) Dietary leucine–an environmental modifier of insulin resistance acting on multiple levels of metabolism. PLoS One 6(6):e21187PubMedCentralPubMedCrossRef
79.
Zurück zum Zitat Scognamiglio R, Testa A, Aquilani R et al (2008) Impairment in walking capacity and myocardial function in the elderly: is there a role for nonpharmacologic therapy with nutritional amino acid supplements? Am J Cardiol 101(Suppl):78E–81EPubMedCrossRef Scognamiglio R, Testa A, Aquilani R et al (2008) Impairment in walking capacity and myocardial function in the elderly: is there a role for nonpharmacologic therapy with nutritional amino acid supplements? Am J Cardiol 101(Suppl):78E–81EPubMedCrossRef
80.
Zurück zum Zitat Mancini M, Rengo F, Lingetti M et al (1992) Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 42:1101–1104PubMed Mancini M, Rengo F, Lingetti M et al (1992) Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 42:1101–1104PubMed
81.
Zurück zum Zitat Iliceto S, Scrutinio D, Bruzzi P et al (1995) Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 26:380–387PubMedCrossRef Iliceto S, Scrutinio D, Bruzzi P et al (1995) Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trial. J Am Coll Cardiol 26:380–387PubMedCrossRef
82.
Zurück zum Zitat Anand I, Chandrashekhan Y, De Giuli F et al (1998) Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12:291–299PubMedCrossRef Anand I, Chandrashekhan Y, De Giuli F et al (1998) Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 12:291–299PubMedCrossRef
83.
Zurück zum Zitat The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure (1999) Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 20:70–76CrossRef The Investigators of the Study on Propionyl-L-Carnitine in Chronic Heart Failure (1999) Study on propionyl-L-carnitine in chronic heart failure. Eur Heart J 20:70–76CrossRef
84.
Zurück zum Zitat Loster H, Miehe K, Punzel M et al (1999) Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 13:537–546PubMedCrossRef Loster H, Miehe K, Punzel M et al (1999) Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe, ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther 13:537–546PubMedCrossRef
85.
Zurück zum Zitat Azuma J, Hasegawa H, Sawamura A et al (1983) Therapy of congestive heart failure with orally administered taurine. Clin Ther 5:398–408PubMed Azuma J, Hasegawa H, Sawamura A et al (1983) Therapy of congestive heart failure with orally administered taurine. Clin Ther 5:398–408PubMed
86.
Zurück zum Zitat Azuma J, Sawamura A, Awata N et al (1985) Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol 8:276–282PubMedCrossRef Azuma J, Sawamura A, Awata N et al (1985) Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol 8:276–282PubMedCrossRef
87.
Zurück zum Zitat Azuma J, Sawamura A, Awata N (1992) Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 56:95–99PubMedCrossRef Azuma J, Sawamura A, Awata N (1992) Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 56:95–99PubMedCrossRef
88.
Zurück zum Zitat Beyranvand MR, Khalafi MK, Roshan VD et al (2011) Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 57:333–337PubMedCrossRef Beyranvand MR, Khalafi MK, Roshan VD et al (2011) Effect of taurine supplementation on exercise capacity of patients with heart failure. J Cardiol 57:333–337PubMedCrossRef
89.
Zurück zum Zitat Chin-Dusting JP, Kaye DM, Lefkovits J et al (1996) Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 27:1207–1213PubMedCrossRef Chin-Dusting JP, Kaye DM, Lefkovits J et al (1996) Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 27:1207–1213PubMedCrossRef
90.
Zurück zum Zitat Rector TS, Bank AJ, Mullen KA et al (1996) Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 93:2135–2141PubMedCrossRef Rector TS, Bank AJ, Mullen KA et al (1996) Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 93:2135–2141PubMedCrossRef
91.
Zurück zum Zitat Hambrecht R, Hilbrich L, Erbs S et al (2000) Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral l-arginine supplementation. J Am Coll Cardiol 35:706–713PubMedCrossRef Hambrecht R, Hilbrich L, Erbs S et al (2000) Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral l-arginine supplementation. J Am Coll Cardiol 35:706–713PubMedCrossRef
92.
Zurück zum Zitat Bednarz B, Jaxa-Chamiec T, Gebalska J et al (2004) L-arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol Pol 60:348–353PubMed Bednarz B, Jaxa-Chamiec T, Gebalska J et al (2004) L-arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol Pol 60:348–353PubMed
93.
Zurück zum Zitat Fontanive P, Saponati G, Iurato A et al (2009) Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure. Med Sci Monit 15:CR606–CR611PubMed Fontanive P, Saponati G, Iurato A et al (2009) Effects of L-arginine on the Minnesota Living with Heart Failure Questionnaire quality-of-life score in patients with chronic systolic heart failure. Med Sci Monit 15:CR606–CR611PubMed
94.
Zurück zum Zitat Gordon A, Hultman E, Kaijser L et al (1995) Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 30:413–418PubMedCrossRef Gordon A, Hultman E, Kaijser L et al (1995) Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 30:413–418PubMedCrossRef
95.
Zurück zum Zitat Andrews R, Greenhaff P, Curtis S et al (1998) The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 19:617–622PubMedCrossRef Andrews R, Greenhaff P, Curtis S et al (1998) The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 19:617–622PubMedCrossRef
96.
Zurück zum Zitat Kuethe F, Krack A, Richartz BM et al (2006) Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie 61:218–222PubMed Kuethe F, Krack A, Richartz BM et al (2006) Creatine supplementation improves muscle strength in patients with congestive heart failure. Pharmazie 61:218–222PubMed
97.
Zurück zum Zitat Cornelissen VA, Defoor JG, Stevens A et al (2010) Effect of creatine supplementation as a potential adjuvant therapy to exercise training in cardiac patients: a randomized controlled trial. Clin Rehabil 24:988–999PubMedCrossRef Cornelissen VA, Defoor JG, Stevens A et al (2010) Effect of creatine supplementation as a potential adjuvant therapy to exercise training in cardiac patients: a randomized controlled trial. Clin Rehabil 24:988–999PubMedCrossRef
98.
Zurück zum Zitat Fumagalli S, Fattirolli F, Guarducci L et al (2011) Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol 34:211–217PubMedCrossRef Fumagalli S, Fattirolli F, Guarducci L et al (2011) Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol 34:211–217PubMedCrossRef
Metadaten
Titel
Amino acids and derivatives, a new treatment of chronic heart failure?
verfasst von
Valentina Carubelli
Anna Isotta Castrini
Valentina Lazzarini
Mihai Gheorghiade
Marco Metra
Carlo Lombardi
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 1/2015
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-014-9436-9

Weitere Artikel der Ausgabe 1/2015

Heart Failure Reviews 1/2015 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.